Released Nov 7, 2018, after the close
10-Q filed Nov 9, 2018, 40 days after period end · 0001493152-18-015583
Q3 2018 · 10-Q
Revenue$6.00M$6.00M +15.5% vs Q3 2017+6.2% vs Q2 2018
Net Income$222.00K$222.00K N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted$0.08$0.08 N/M vs Q3 2017N/M vs Q2 2018
Operating Income$370,000N/M
Operating Cash Flowderived$289,000N/M
Free Cash Flowderived$278,000N/M
Margins · derived
Operating margin6.2%+7.2 pt vs Q3 2017
Net margin3.7%+7.2 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $6.00M | $5.20M | $5.44M | $6.08M |
| Net Income | $222.00K | -$184.00K | -$573.00K | -$1.35M |
| EPS Diluted | $0.08 | -$0.07 | -$0.31 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR